Related Experiment Video
Updated: Sep 10, 2025

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
APOL1 Mediated Kidney Disease: A Review and Look Toward the Future
Vinay Srinivasan1, Paolo Nikolai So2, Edward P K Kwakyi3
1Division of Nephrology, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, NJ.
Insights
Genetic factors like APOL1 risk alleles contribute to kidney disease disparities in people of African ancestry. Understanding these genetic links and potential triggers is key for developing targeted treatments and genetic testing strategies.
Area of Science:
- Nephrology
- Genetics
- Epidemiology
Background:
- Individuals of recent African ancestry experience disproportionately high rates of kidney disease.
- The discovery of Apolipoprotein L1 (APOL1) gene risk alleles (G1 and G2) offers insights into these health disparities.
- APOL1 high-risk alleles may provide evolutionary protection against Trypanosoma parasites but are linked to kidney disease in certain populations.
Purpose of the Study:
- To review the development and clinical implications of APOL1 risk alleles in kidney disease.
- To discuss the 'second hit' hypothesis involving genetic, environmental, and inflammatory factors.
- To propose a framework for nephrologists regarding APOL1 genetic testing.
Main Methods:
- Review of scientific literature on APOL1 gene, risk alleles, and kidney disease.
- Discussion of cellular toxicity mechanisms and therapeutic targets.
- Analysis of clinical trial data, including inaxaplin's progression to Phase 3.
Main Results:
- Approximately 6 million African Americans possess a high-risk APOL1 genotype.
- Not all individuals with high-risk genotypes develop kidney disease, suggesting additional contributing factors.
- Targeted therapies like inaxaplin are being investigated for APOL1-associated kidney disease.
Conclusions:
- APOL1 risk alleles are significant contributors to kidney disease disparities.
- Further research into genetic, environmental, and inflammatory triggers is crucial.
- Accessible genetic testing and targeted therapies hold promise for managing APOL1-related kidney disease.
Abstract:
Individuals of recent African ancestry are disproportionately affected by kidney disease. The discovery of the Apolipoprotein L1 (APOL1) gene and, subsequently, the G1 and G2 risk alleles has helped to understand some of these disparities. The APOL1 gene does not appear to be necessary for normal kidney function, and the high-risk alleles appear to be gain of function mutations offering protection against Trypanosoma species. In the United States, ∼6 million African Americans have a high-risk genotype. However, not all patients with high-risk genotypes will develop kidney disease, leading to the idea of a second hit hypothesis by certain genetic, environmental, and inflammatory triggers. Recent clinical trials have focused on the different postulated mechanisms of cellular toxicity, and one promising candidate, inaxaplin, has advanced to a phase 3 study. This mini-review discusses the development of APOL1 risk alleles, clinical implications of a high-risk genotype, and a suggested framework for nephrologists to pursue genetic testing in countries where it is easily accessible.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury V: Interprofessional Care
Kidney Transplant I: Introduction

